4basebio (AIM:4BB) expanded its DNA manufacturing offering to support production of starting material for personalised mRNA medicines.
The AIM-listed company, which specialises in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, said the upgrade to its Cambridge-based high quality (HQ) and current Good Manufacturing Practice (cGMP) operations cuts turnaround times and enables smaller, patient-specific batch sizes with rapid batch release.
"Personalised medicine places a very different set of demands on manufacturing than traditional biologics, including shorter turnaround times, smaller batch sizes, and zero tolerance for variability between batches," said Chief Operating Officer Scott Lorimer.
Chief Executive Dr Amy Walker said traditional plasmid DNA was "never designed" for small personalised medicine batches, carrying time delays, added costs and contamination risks, while the company's cell-free synthetic DNA platform produces a high-purity template on a timeline of weeks rather than months.
The announcement follows last month's news that Moderna and Merck's personalised mRNA cancer vaccine, intismeran autogene, succeeded in a Phase 3 trial for high-risk melanoma, the first positive late-stage trial for an individualised mRNA cancer vaccine.
The global personalised cancer vaccine market was valued at approximately $200 million in 2024 and is projected to reach $1.4 billion by 2030, according to Grand View Research.
4basebio's Cambridge sites include custom-built cleanrooms for HQ and cGMP operations alongside research-use-only facilities for pre-clinical work.
News Intelligence what this means for the company
4basebio upgraded its Cambridge manufacturing to produce smaller, patient-specific batches of synthetic DNA for personalised mRNA medicines, cutting turnaround times from months to weeks. The move targets a market valued at $200 million in 2024 and projected to reach $1.4 billion by 2030, following Moderna and Merck's Phase 3 success with an individualised mRNA cancer vaccine last month.
The upgrade positions 4basebio's cell-free enzymatic platform as a supply-chain enabler for the emerging personalised medicine segment, where traditional plasmid DNA manufacturing is ill-suited. Revenue impact depends on conversion of this capability into commercial partnerships and clinical supply agreements.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
